Key result
In a severe mouse model of hypertrophic cardiomyopathy, decreased expression of miR-1 and miR-133a commenced at a pre-disease stage, and 16 miRNAs were dysregulated at end-stage disease.
Authors
No takes yet. Share an insight, caveat, or question.
Early miRNA changes in this HCM mouse model are hypothesis-generating; human studies needed before biomarker or therapeutic exploration.
Bagnall et al. (2012) studied Hypertrophic Cardiomyopathy and Heart Failure. TnI-203/MHC-403 double mutation (DBL mouse model) vs. Non-transgenic (NTG) mice was evaluated on Global miRNA expression profiling in ventricles during early and end-stage HCM. In a severe mouse model of hypertrophic cardiomyopathy, decreased expression of miR-1 and miR-133a commenced at a pre-disease stage, and 16 miRNAs were dysregulated at end-stage disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: